A Randomized, Double-blinded, Placebo-controlled Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of the Recombinant SARS-CoV-2 Vaccine (CHO Cell) for the Prevention of COVID-19 in Adults Aged 18 Years and Above
Latest Information Update: 21 Apr 2023
At a glance
- Drugs 202-CoV (Primary) ; Alum; CpG
- Indications COVID 2019 infections
- Focus Pharmacodynamics
- Sponsors Shanghai Zerun Biotechnology Co
Most Recent Events
- 18 Apr 2023 Planned End Date changed from 1 Oct 2022 to 1 Nov 2023.
- 13 Mar 2023 Status changed from active, no longer recruiting to completed, according to a Shanghai Zerun Biotechnology company pipeline.
- 27 Aug 2022 Status changed from recruiting to active, no longer recruiting.